吡格列酮
内分泌学
内科学
海马结构
海马体
胰岛素抵抗
星形胶质细胞
医学
萧条(经济学)
兴奋剂
糖尿病
过氧化物酶体增殖物激活受体
2型糖尿病
下调和上调
受体
生物
中枢神经系统
宏观经济学
经济
基因
生物化学
作者
Ying Yiu Lam,Sheng Feng Tsai,Pei Chun Chen,Yu Min Kuo,Yun Wen Chen
标识
DOI:10.1016/j.biopha.2021.111734
摘要
The prevalence of diabetes is rapidly increasing worldwide and is highly associated with the incidence of depression. Pioglitazone, a Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist, is widely used for treating patients with type 2 diabetes. However, whether pioglitazone alleviates metabolic disorder-related depression and astrocytic deficits remains unclear. Here we showed that 12 weeks of high-fat diet (HFD) feeding (from 8- to 20-week-old) induced not only obesity and insulin resistance, but also depression-like behaviors in mice. Astrocytic activation, a sign closely associated with depression, was also evident in the ventral hippocampus. Four weeks of pioglitazone (10 or 20 mg/kg, daily, from 20- to 24-week-old) treatment alleviated the HFD-induced glucose-metabolic dysfunctions, upregulation of ventral hippocampal GFAP, reduction of the total process lengths and the number of branch points of the ventral hippocampal CA1 GFAP-immunoreactive astrocytes and depressive phenotypes but had no effect on anxiety-like behaviors or hippocampus-related learning and memory in mice. These findings suggest that pioglitazone could be a potential therapeutic agent for metabolic disorders and associated depression.
科研通智能强力驱动
Strongly Powered by AbleSci AI